Vol 43, No 5 (May 2022) - Acta Pharmacologica Sinica

Xin Zhou, Ya-ni Zhang, Fang-fang Li, Zhao Zhang, Li-yuan Cui, Hong-yuan He, Xu Yan, Wen-bin He, Hong-shuo Sun, Zhong-ping Feng, Shi-feng Chu, Nai-hong Chen

Cardiomyocyte peroxisome proliferator-activated receptor α is essential for energy metabolism and extracellular matrix homeostasis during pressure overload-induced cardiac remodeling Pages (1231–1242)

Xia Wang, Xin-xin Zhu, Shi-yu Jiao, Dan Qi, Bao-qi Yu, Guo-min Xie, Ye Liu, Yan-ting Song, Qing Xu, Qing-bo Xu, Frank J. Gonzalez, Jie Du, Xiao-min Wang, Ai-juan Qu

Glibenclamide alleviates β adrenergic receptor activation- induced cardiac inflammation Pages (1243–1250)

Ning Cao, Jing-jing Wang, Ji-min Wu, Wen-li Xu, Rui Wang, Xian-da Chen, Ye-nan Feng, Wen-wen Cong, You-yi Zhang, Han Xiao, Er-dan Dong

TFEB, a master regulator of autophagy and biogenesis, unexpectedly promotes apoptosis in response to the cyclopentenone prostaglandin 15d-PGJ2 Pages (1251–1263)

Chuan-bin Yang, Jia Liu, Benjamin Chun-Kit Tong, Zi-ying Wang, Zhou Zhu, Cheng-fu Su, Sravan Gopalkrishnashetty Sreenivasmurthy, Jia-xi Wu, Ashok Iyaswamy, Senthilkumar Krishnamoorthi, Shi-ying Huang, King-ho Cheung, Ju-xian Song, Jie-qiong Tan, Jia-hong Lu, Min Li

A novel resveratrol analog upregulates sirtuin 1 and inhibits inflammatory cell infiltration in acute pancreatitis Pages (1264–1273)

Zheng-nan Ren, Jun Yang, Meng-ya Zhang, Yi-wen Huang, Dong-xiao Song, Xun Sun, Li-long Pan, Jia Sun

Tetrandrine alleviates silicosis by inhibiting canonical and non-canonical NLRP3 inflammasome activation in lung macrophages Pages (1274–1284) Open

Mei-yue Song, Jia-xin Wang, You-liang Sun, Zhi-fa Han, Yi-tian Zhou, Ying Liu, Tian-hui Fan, Zhao-guo Li, Xian-mei Qi, Ya Luo, Pei-ran Yang, Bai-cun Li, Xin-ri Zhang, Jing Wang, Chen Wang

Berberine remodels adipose tissue to attenuate metabolic disorders by activating sirtuin 3 Pages (1285–1298)

Dan Li, Chao Yang, Jian-zhong Zhu, Eduardo Lopez, Tian Zhang, Qiang Tong, Cheng Peng, Li-gen Lin

Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via suppressing ERK/c-fos/NFATc1 pathway, and subsequently inhibiting subchondral osteoclast fusion Pages (1299–1310)

Chao Fang, Jia-wei Guo, Ya-jun Wang, Xiao-qun Li, Hao Zhang, Jin Cui, Yan Hu, Ying-ying Jing, Xiao Chen, Jia-can Su

The m⁶A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG Pages (1311–1323)

Liu-shan Chen, Meng Zhang, Peng Chen, Xiao-feng Xiong, Pei-qing Liu, Hai-bin Wang, Jun-jian Wang, Juan Shen

Gout-associated monosodium urate crystal-induced necrosis is independent of NLRP3 activity but can be suppressed by combined inhibitors for multiple signaling pathways Pages (1324–1336)

Chun-su Zhong, Bo Zeng, Jia-hao Qiu, Li-hui Xu, Mei-yan Zhong, Yuan-ting Huang, Rong Xu, Si-ying Liu, Qing-bing Zha, Bo Hu, Dong-yun Ou-Yang, Xian-hui He

Vol 43, No 5 (May 2022): Acta Pharmacologica Sinica

*See the special featured articles marked

Editorial

All about NASH: disease biology, targets, and opportunities on the road to NASH drugs Pages (1101–1102)

Review Article

Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease Pages (1103–1119)

FXR: structures, biology, and drug development for NASH and fibrosis diseases Pages (1120–1132)

The role of REV-ERB in NASH Pages (1133–1140)

Mitochondria homeostasis: Biology and involvement in hepatic steatosis to NASH Pages (1141–1155)

GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis Pages (1156–1166)

The miR-23–27–24 cluster: an emerging target in NAFLD pathogenesis Pages (1167–1179)

Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis Pages (1180–1190)

Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis Pages (1191–1199)

Histological assessment based on liver biopsy: the value and challenges in NASH drug development Pages (1200–1209)

Perspective

NASH: regulatory considerations for clinical drug development and U.S. FDA approval Pages (1210–1214)

Research Highlight

Keeping time on liver fibrosis Pages (1215–1216) Open

Article

Neuronal chemokine-like-factor 1 (CKLF1) up-regulation promotes M1 polarization of microglia in rat brain after stroke Pages (1217–1230)

Cardiomyocyte peroxisome proliferator-activated receptor α is essential for energy metabolism and extracellular matrix homeostasis during pressure overload-induced cardiac remodeling Pages (1231–1242)

Glibenclamide alleviates β adrenergic receptor activation- induced cardiac inflammation Pages (1243–1250)

TFEB, a master regulator of autophagy and biogenesis, unexpectedly promotes apoptosis in response to the cyclopentenone prostaglandin 15d-PGJ2 Pages (1251–1263)

A novel resveratrol analog upregulates sirtuin 1 and inhibits inflammatory cell infiltration in acute pancreatitis Pages (1264–1273)

Tetrandrine alleviates silicosis by inhibiting canonical and non-canonical NLRP3 inflammasome activation in lung macrophages Pages (1274–1284) Open

Berberine remodels adipose tissue to attenuate metabolic disorders by activating sirtuin 3 Pages (1285–1298)

Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via suppressing ERK/c-fos/NFATc1 pathway, and subsequently inhibiting subchondral osteoclast fusion Pages (1299–1310)

The m⁶A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG Pages (1311–1323)

Gout-associated monosodium urate crystal-induced necrosis is independent of NLRP3 activity but can be suppressed by combined inhibitors for multiple signaling pathways Pages (1324–1336)

Table of Contents

Cover Image

Vol 43, No 5 (May 2022): Acta Pharmacologica Sinica

*See the special featured articles marked

Editorial

All about NASH: disease biology, targets, and opportunities on the road to NASH drugs Pages (1101–1102)

Review Article

Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease Pages (1103–1119)

FXR: structures, biology, and drug development for NASH and fibrosis diseases Pages (1120–1132)

The role of REV-ERB in NASH Pages (1133–1140)

Mitochondria homeostasis: Biology and involvement in hepatic steatosis to NASH Pages (1141–1155)

GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis Pages (1156–1166)

The miR-23–27–24 cluster: an emerging target in NAFLD pathogenesis Pages (1167–1179)

Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis Pages (1180–1190)

Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis Pages (1191–1199)

Histological assessment based on liver biopsy: the value and challenges in NASH drug development Pages (1200–1209)

Perspective

NASH: regulatory considerations for clinical drug development and U.S. FDA approval Pages (1210–1214)

Research Highlight

Keeping time on liver fibrosis Pages (1215–1216) Open

Article

Neuronal chemokine-like-factor 1 (CKLF1) up-regulation promotes M1 polarization of microglia in rat brain after stroke Pages (1217–1230)

Cardiomyocyte peroxisome proliferator-activated receptor α is essential for energy metabolism and extracellular matrix homeostasis during pressure overload-induced cardiac remodeling Pages (1231–1242)

Glibenclamide alleviates β adrenergic receptor activation- induced cardiac inflammation Pages (1243–1250)

TFEB, a master regulator of autophagy and biogenesis, unexpectedly promotes apoptosis in response to the cyclopentenone prostaglandin 15d-PGJ2 Pages (1251–1263)

A novel resveratrol analog upregulates sirtuin 1 and inhibits inflammatory cell infiltration in acute pancreatitis Pages (1264–1273)

Tetrandrine alleviates silicosis by inhibiting canonical and non-canonical NLRP3 inflammasome activation in lung macrophages Pages (1274–1284) Open

Berberine remodels adipose tissue to attenuate metabolic disorders by activating sirtuin 3 Pages (1285–1298)

Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via suppressing ERK/c-fos/NFATc1 pathway, and subsequently inhibiting subchondral osteoclast fusion Pages (1299–1310)

The m6A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG Pages (1311–1323)

Gout-associated monosodium urate crystal-induced necrosis is independent of NLRP3 activity but can be suppressed by combined inhibitors for multiple signaling pathways Pages (1324–1336)

Table of Contents

Cover Image

The m⁶A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG Pages (1311–1323)